China Pharma Holdings (CPHI) Total Current Liabilities (2010 - 2026)

China Pharma Holdings has reported Total Current Liabilities for 17 years, with the latest figure at $7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 41.89% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (up 41.89% YoY), and the FY2025 full-year result was $7.4 million, up 47.5% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $7.3 million, down from $7.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $12.7 million in Q4 2022, with the low at $4.7 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $7.8 million across 5 years, with a median of $7.1 million in 2023.
• Annual changes were most pronounced in 2024 — Total Current Liabilities slumped 55.32% — and 2025, when it jumped 47.5%.
• China Pharma Holdings' Total Current Liabilities stood at $12.7 million in 2022, then slumped by 46.46% to $6.8 million in 2023, then retreated by 26.44% to $5.0 million in 2024, then soared by 47.5% to $7.4 million in 2025, then slipped by 1.79% to $7.3 million in 2026.
• The last three Total Current Liabilities figures came in at $7.3 million (Q1 2026), $7.4 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.